Whitehouse J M, Crowther D, Bateman C J, Beard M E, Malpas J S
Br Med J. 1972 Feb 19;1(5798):482-3. doi: 10.1136/bmj.1.5798.482.
In a preliminary study a new antitumour antibiotic, adriamycin, was found to be capable of inducing complete remission in 6 out of 17 patients with acute lymphoblastic leukaemia and in one out of four with lymphoblastic lymphosarcoma despite the fact that these patients had either failed to respond or had relapsed after chemotherapy with agents recognized to be potentially successful in each condition. In five cases of acute lymphoblastic leukaemia adriamycin was used in combination with cytosine arabinoside-three achieved complete remission and two good partial remissions. This combination seems to merit further study in patients who have relapsed on the more conventional chemotherapeutic regimens in acute lymphoblastic leukaemia.In 13 patients with acute myelogenous leukaemia previously treated with daunorubicin and cytosine arabinoside no remissions were obtained with the dose range used.
在一项初步研究中，发现一种新的抗肿瘤抗生素阿霉素能够使17例急性淋巴细胞白血病患者中的6例以及4例淋巴细胞性淋巴肉瘤患者中的1例实现完全缓解，尽管这些患者在使用被认为对每种病症可能有效的药物进行化疗后要么没有反应，要么已经复发。在5例急性淋巴细胞白血病患者中，阿霉素与阿糖胞苷联合使用，3例实现了完全缓解，2例实现了良好的部分缓解。对于在急性淋巴细胞白血病中采用更传统化疗方案后复发的患者，这种联合用药似乎值得进一步研究。在13例先前接受过柔红霉素和阿糖胞苷治疗的急性髓性白血病患者中，在所使用的剂量范围内未获得缓解。
